KNSA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
243.6M
+13.7%
214.3M
+6.0%
202.1M
+11.8%
180.9M
+15.3%
156.8M
Cost of Revenue
23.6M
+13.3%
20.8M
-0.7%
20.9M
+3.4%
20.3M
+8.9%
18.6M
Gross Profit
220.0M
+13.7%
193.5M
+6.8%
181.2M
+12.8%
160.6M
+16.2%
138.2M
Operating Expenses
192.8M
+17.4%
164.2M
+1.7%
161.4M
+18.2%
136.6M
+15.7%
118.0M
R&D
40.9M
+48.9%
27.5M
-20.6%
34.6M
+43.2%
24.2M
+28.9%
18.8M
SG&A
63.9M
+4.4%
61.2M
+7.7%
56.8M
+15.6%
49.1M
+4.8%
46.9M
Operating Income
27.2M
-7.1%
29.3M
+48.1%
19.8M
-17.7%
24.0M
+19.2%
20.2M
EBITDA
27.7M
-7.0%
29.7M
+46.9%
20.2M
-17.2%
24.4M
+19.1%
20.5M
Net Income
25.4M
+12.6%
22.6M
+59.1%
14.2M
-23.0%
18.4M
+3.4%
17.8M
EPS (Basic)
$0.33
+10.0%
$0.30
+57.9%
$0.19
-24.0%
$0.25
+4.2%
$0.24
EPS (Diluted)
$0.30
+11.1%
$0.27
+58.8%
$0.17
-26.1%
$0.23
+0.0%
$0.23
Shares (Diluted)
83.4M
+1.2%
82.4M
+0.8%
81.8M
+2.2%
80.0M
+2.7%
77.9M
Kiniksa Pharmaceuticals International (KNSA) โ€” Financials